S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:CMPI

Checkmate Pharmaceuticals Stock Forecast, Price & News

$3.58
-0.16 (-4.28%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.56
$3.62
50-Day Range
$3.58
$4.87
52-Week Range
$3.53
$23.10
Volume
1,885 shs
Average Volume
45,099 shs
Market Capitalization
$77.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.27
30 days | 90 days | 365 days | Advanced Chart
Receive CMPI News and Ratings via Email

Sign-up to receive the latest news and ratings for Checkmate Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Checkmate Pharmaceuticals logo

About Checkmate Pharmaceuticals

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Headlines

Checkmate Pharmaceuticals Announces CEO Transition
October 27, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CMPI
Fax
N/A
Employees
25
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$3.77 per share

Profitability

Net Income
$-36.91 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
8,090,000
Market Cap
$77.44 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/12/2021
Today
11/28/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
4/04/2022

MarketRank

Overall MarketRank

2.39 out of 5 stars

Medical Sector

186th out of 1,391 stocks

Biological Products, Except Diagnostic Industry

28th out of 201 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -












Checkmate Pharmaceuticals (NASDAQ:CMPI) Frequently Asked Questions

Is Checkmate Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Checkmate Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Checkmate Pharmaceuticals stock.
View analyst ratings for Checkmate Pharmaceuticals
or view top-rated stocks.

Are investors shorting Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals saw a increase in short interest in October. As of October 15th, there was short interest totaling 66,900 shares, an increase of 23.0% from the September 30th total of 54,400 shares. Based on an average daily trading volume, of 29,800 shares, the days-to-cover ratio is presently 2.2 days. Currently, 1.5% of the company's shares are short sold.
View Checkmate Pharmaceuticals' Short Interest
.

When is Checkmate Pharmaceuticals' next earnings date?

Checkmate Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for Checkmate Pharmaceuticals
.

How were Checkmate Pharmaceuticals' earnings last quarter?

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.71) by $0.02.
View Checkmate Pharmaceuticals' earnings history
.

What price target have analysts set for CMPI?

3 Wall Street analysts have issued 12 month price targets for Checkmate Pharmaceuticals' stock. Their forecasts range from $7.00 to $29.00. On average, they expect Checkmate Pharmaceuticals' share price to reach $18.33 in the next twelve months. This suggests a possible upside of 412.1% from the stock's current price.
View analysts' price targets for Checkmate Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Checkmate Pharmaceuticals' key executives?

Checkmate Pharmaceuticals' management team includes the following people:
  • Mr. Barry A. Labinger, CEO, Pres & Director (Age 57, Pay $724.92k)
  • Dr. Arthur M. Krieg, Founder, Chief Scientific Officer, Treasurer, Sec. & Independent Director (Age 64) (LinkedIn Profile)
  • Dr. James E. Wooldridge M.D., Chief Medical Officer (Age 55, Pay $536.32k)
  • Dr. Kleem Chaudhary Ph.D., Chief Bus. Officer (Age 45, Pay $482.1k)
  • Mr. Robert F. Dolski, CFO & Principal Accounting Officer (Age 50)
  • Ms. Katherine A. Eade, Gen. Counsel (Age 47)

What other stocks do shareholders of Checkmate Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkmate Pharmaceuticals investors own include Oak Street Health (OSH), Adobe (ADBE), Berkshire Hathaway (BRK.A), Lockheed Martin (LMT), Tesla (TSLA), Acutus Medical (AFIB), BigCommerce (BIGC), Freeline Therapeutics (FRLN), Rocket Companies (RKT) and Agnico Eagle Mines (AEM).

When did Checkmate Pharmaceuticals IPO?

(CMPI) raised $75 million in an initial public offering (IPO) on Friday, August 7th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and BMO Capital Markets served as the underwriters for the IPO and BTIG was co-manager.

What is Checkmate Pharmaceuticals' stock symbol?

Checkmate Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMPI."

Who are Checkmate Pharmaceuticals' major shareholders?

Checkmate Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (0.24%).
View institutional ownership trends for Checkmate Pharmaceuticals
.

Which institutional investors are buying Checkmate Pharmaceuticals stock?

CMPI stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc..
View insider buying and selling activity for Checkmate Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Checkmate Pharmaceuticals?

Shares of CMPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Checkmate Pharmaceuticals' stock price today?

One share of CMPI stock can currently be purchased for approximately $3.58.

How much money does Checkmate Pharmaceuticals make?

Checkmate Pharmaceuticals has a market capitalization of $77.44 million.

How many employees does Checkmate Pharmaceuticals have?

Checkmate Pharmaceuticals employs 25 workers across the globe.

What is Checkmate Pharmaceuticals' official website?

The official website for Checkmate Pharmaceuticals is www.checkmatepharma.com.

Where are Checkmate Pharmaceuticals' headquarters?

Checkmate Pharmaceuticals is headquartered at 245 MAIN STREET 2ND FLOOR, CAMBRIDGE MA, 02142.

How can I contact Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals' mailing address is 245 MAIN STREET 2ND FLOOR, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-682-3625 or via email at [email protected].


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.